Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | MEN1 | O00255 | 5/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | USP2 | O75604 | 4/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.34 |
| ▸ | FYN | P06241 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196791 | 0.73 | KDM4E (0.30) | CYP1A2HIF1A | |
| SCHEMBL971910 | 0.72 | CYP11B1 (0.38) | ALDH1A1MEN1KMT2AUSP2CYP2D6 | |
| SCHEMBL69777 | 0.71 | KMT2A (0.41) | ALDH1A1MEN1KMT2AADORA2ACYP3A4 | |
| SCHEMBL17701188 | 0.71 | SCN9A (0.31) | — | |
| SCHEMBL196321 | 0.70 | LPL (0.41) | ALDH1A1CYP2D6CYP2C19ADORA2ACYP1A2 | |
| SCHEMBL1315590 | 0.69 | MAPT (0.42) | KMT2ACYP2D6CYP2C19TP53CYP11B1 | |
| SCHEMBL998693 | 0.68 | ATM (0.37) | CYP11B1CYP11B2PIM1 | |
| SCHEMBL1416238 | 0.68 | RAB9A (0.39) | ALDH1A1MEN1KMT2ACYP1A2HSD17B10 | |
| SCHEMBL1415919 | 0.68 | ENPP3 (0.41) | ALDH1A1MEN1KMT2AADORA3PIM1 | |
| SCHEMBL2099096 | 0.68 | KDM4E (0.52) | ALDH1A1MEN1KMT2AUSP2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1080104-B1 | CERTAIN HETEROARYL SUBSTITUTED THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | NOVARTIS AG (CH) | 2005-02-09 | — | — | EP | claimed |
| US-6689801-B2 | CARDIOVASCULAR DISORDERS; ANTIISCHEMIC AGENTS; HYPOTENSIVE AGENTS; GASTROINTESTINAL DISORDERS | NOVARTIS AG (CH) | 2004-02-10 | — | — | US | claimed |
| US-20030018057-A1 | Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme | FINK CYNTHIA ANNE (US) | 2003-01-23 | — | — | US | claimed |
| US-6426354-B1 | CARDIOVASCULAR DISORDERS; RESPIRATORY SYSTEM DISORDERS; BRAIN DISORDERS | NOVARTIS AG (CH) | 2002-07-30 | — | — | US | claimed |
| EP-1080104-A1 | CERTAIN HETEROARYL SUBSTITUTED THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | Novartis AG (CH) | 2001-03-07 | — | — | EP | claimed |
| WO-1999055723-A1 | CERTAIN HETEROARYL SUBSTITUTED THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | NOVARTIS AG (CH) | 1999-11-04 | — | — | WO | claimed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-101255170-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-09-03 | — | — | CN | disclosed |
| CN-101172981-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-05-07 | — | — | CN | disclosed |
| CN-100366624-C | 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds | OTSUKA PHARMA CO LTD (JP) | 2008-02-06 | — | — | CN | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1080104-B1 | CERTAIN HETEROARYL SUBSTITUTED THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | NOVARTIS AG (CH) | 2005-02-09 | — | — | EP | disclosed |
| US-6689801-B2 | CARDIOVASCULAR DISORDERS; ANTIISCHEMIC AGENTS; HYPOTENSIVE AGENTS; GASTROINTESTINAL DISORDERS | NOVARTIS AG (CH) | 2004-02-10 | — | — | US | disclosed |
| US-20030018057-A1 | Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme | FINK CYNTHIA ANNE (US) | 2003-01-23 | — | — | US | disclosed |
| US-6426354-B1 | CARDIOVASCULAR DISORDERS; RESPIRATORY SYSTEM DISORDERS; BRAIN DISORDERS | NOVARTIS AG (CH) | 2002-07-30 | — | — | US | disclosed |
| EP-1080104-A1 | CERTAIN HETEROARYL SUBSTITUTED THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | Novartis AG (CH) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999055723-A1 | CERTAIN HETEROARYL SUBSTITUTED THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | NOVARTIS AG (CH) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018057-A1 | Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme | ECE1, ECE2, EDNRB | ALDH1A1 145/4885MEN1 2777/4885KMT2A 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.